Login to Your Account

IDM, Sanofi-Synthélabo Enter Deal Potentially Worth $545M

By James Etheridge

Wednesday, January 23, 2002
PARIS Immuno-Designed Molecules SA, a Paris-based company specialized in the development of cellular immunotherapies for cancer, signed a co-development agreement with the French pharmaceutical company Sanofi-Synthélabo SA covering the whole range of IDM’s “cell drugs” for cancer.

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription